Open access
Aug 2026
Treatment Sequencing of CDK4/6 Inhibitors in Bone-Only Hormone Receptor-Positive Metastatic Breast Cancer: Multi-Center Real-World Data Revealing a Numerical Trend Favoring Later-Line Use
Simple Summary Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy are standard first-line treatments for hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC). However, the optimal sequencing of CDK4/6i for patients presenting with bone-only disease (BoD) remains un...
S. Yıldırım, Büşra Bülbül, Bekir Ucun et al.
· Cancers · 0 citations